Clinically relevant behavioral endpoints in a recurrent nitroglycerin migraine model in rats

Area of Science:

• Neuroscience
• Pharmacology
• Animal Models

Background:

• The rat model of migraine using nitroglycerin (NTG) requires further validation.
• Comparing single versus recurrent NTG administration is crucial for understanding migraine pathophysiology.
• Assessing behavioral endpoints aligned with International Classification of Headache Disorders (ICHD-3) criteria is necessary.

Purpose of the Study:

• To validate a recurrent nitroglycerin (NTG) rat model for migraine research.
• To compare the behavioral effects of single versus repeated NTG administration.
• To evaluate the efficacy of sumatriptan in mitigating NTG-induced migraine-like behaviors.

Main Methods:

• Rats received single or repeated doses of NTG (10 mg/kg) or saline.
• Behavioral assessments included light/dark activity, photophobia, facial pain ratings, and tail-dip tests.
• Sumatriptan (0.0, 0.3, 1.0 mg/kg) was administered in a rescue experiment.

Main Results:

• Repeated NTG injections, but not single doses, induced photophobia, reduced activity, and decreased weight gain.
• Sumatriptan dose-dependently attenuated hypoactivity and reduced facial pain expressions.
• Sumatriptan also reversed NTG-induced weight alterations.

Conclusions:

• A recurrent NTG rat model exhibits significant clinical homologies to human migraine.
• This validated model is suitable for screening novel migraine pharmacotherapies.
• The findings support the use of this model for preclinical migraine drug development.